Skip to content

Warby Parker WRBY Operating Lease Liability Payments - 2025 (Lessee)

Operating Lease Liability Payments - 2025 (Lessee) at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Revenue$242.4M+8.3%
Gross profit$131.0M+4.0%
Operating income$1.7M-32.5%
Net income$3.2M-8.5%
EPS (diluted)$0.030.0%

Balance sheet

See full
Cash & equivalents$288.2M+8.7%
Total debt$237.6M+6.2%
Total equity$375.8M+6.1%
Total assets$736.4M+7.9%

Cash flow

See full
Operating cash flow$24.5M-16.5%
CapEx$16.1M-0.1%
Free cash flow$8.4M-36.6%

Valuation

See full
Market cap$3.15B+17.1%

Profitability

See full
Gross margin53.4%-1.8pp
Operating margin-0.7%-0.3pp
Net margin0.1%0.0pp
FCF margin4.5%-0.8pp

Returns & leverage

See full
Return on equity0.2%+0.1pp
Debt / equity0.6×0.0×
Current ratio2.3×-0.4×

Where this comes from

Reported directly by Warby Parker in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: Warby Parker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Warby Parker's operating lease liability payments - 2025 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Warby Parker's operating lease liability payments - 2025 (lessee)?
Warby Parker (WRBY) reported operating lease liability payments - 2025 (lessee) of $32.86M in Q1 2026.
How has Warby Parker's operating lease liability payments - 2025 (lessee) changed year-over-year?
Warby Parker's operating lease liability payments - 2025 (lessee) decreased by 8.5% year-over-year, from $35.9M to $32.86M.
What is the long-term trend for Warby Parker's operating lease liability payments - 2025 (lessee)?
Over 4 years (2021 to 2025), Warby Parker's operating lease liability payments - 2025 (lessee) has grown at a 15.9% compound annual growth rate (CAGR), from $23.12M to $41.73M.